Srinivas Sriramula

Dr. Srinivas Sriramula

Pharmacology and Toxicology, East Carolina University, Brody School of Medicine, Greenville, North Carolina, USA
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2010 in Hypertension
Verified
Journal Article
Closed access
PDF file
PSPeng Shi
Peng Shi
CDCarlos Diez-Freire
Carlos Diez-Freire
JJJoo Yun Jun
Joo Yun Jun
YQYanfei Qi
Yanfei Qi
MKMichael J. Katovich
Michael J. Katovich
MRMohan K. Raizada
Mohan K. Raizada
Accumulating evidence indicates a key role of inflammation in hypertension and cardiovascular disorders. However, the role of inflammatory processes in neurogenic hypertension remains to be determined. Thus, our objective in the present study was to test the hypothesis that activation of microglial cells and the generation of proinflammatory cytokines in the paraventricular nucleus (PVN) contribute to neurogenic hypertension. Intracerebroventricular infusion of minocycline, an anti-inflammatory antibiotic, caused a significant attenuation of mean arterial pressure, cardiac hypertrophy, and plasma norepinephrine induced by chronic angiotensin II infusion. This was associated with decreases in the numbers of activated microglia and mRNAs for interleukin (IL) 1β, IL-6, and tumor necrosis factor-α, and an increase in the mRNA for IL-10 in the PVN. Overexpression of IL-10 induced by recombinant adenoassociated virus-mediated gene transfer in the PVN mimicked the antihypertensive effects of minocycline. Furthermore, acute application of a proinflammatory cytokine, IL-1β, into the left ventricle or the PVN in normal rats resulted in a significant increase in mean arterial pressure. Collectively, this indicates that angiotensin II induced hypertension involves activation of microglia and increases in proinflammatory cytokines in the PVN. These data have significant implications on the development of innovative therapeutic strategies for the control of neurogenic hypertension.

1 May 2008 in Hypertension
Verified
Journal Article
Open access
PDF file
Srinivas SriramulaSrinivas Sriramula
Srinivas Sriramula
MHMasudul Haque
Masudul Haque
DMDewan S.A. Majid
Dewan S.A. Majid
JFJoseph Francis
Joseph Francis
Hypertension is considered a low-grade inflammatory condition induced by various proinflammatory cytokines, including tumor necrosis factor (TNF)-α. Recent studies have implicated an involvement of TNF-α in the development of salt-sensitive hypertension induced by angiotensin II (Ang II). To understand further the relationship between TNF-α and Ang II, we examined the responses to Ang II in TNF-α knockout (TNF-α−/−) mice in the present study. A continuous infusion of Ang II (1 μg/kg per minute) for 2 weeks was given to both TNF-α−/−and wild-type (WT) mice with implanted osmotic minipumps. Daily measurement of water intake, salt intake, and urine output were performed using metabolic cages. Blood pressure was monitored continuously with implanted radiotelemetry. Ang II administration for 2 weeks caused increases in salt (0.2±0.07 to 5.6±0.95 mL/d) and water (5.4±0.34 to 11.5±1.2 mL/d) intake and in mean arterial pressure (115±1 to 151±3 mm Hg) in wild-type mice, but these responses were absent in TNF-α−/−mice (0.2±0.04 to 0.3±0.09 mL/d, 5.5±0.2 to 6.1±0.07 mL/d, and 113±2 to 123±3 mm Hg, respectively). Cardiac hypertrophy induced by Ang II was significantly attenuated in TNF-α−/−mice compared with wild-type mice. In a group of TNF-α−/−mice, when replacement therapy was made with recombinant TNF-α, Ang II induced similar responses in salt appetite, mean arterial pressure, and cardiac hypertrophy, as observed in wild-type mice. These results suggest that TNF-α plays a mechanistic role in mediating chronic Ang II–induced effects on salt appetite and blood pressure, as well as on cardiac hypertrophy.

15 October 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
VSVinayak Shenoy
Vinayak Shenoy
AFAnderson J. Ferreira
Anderson J. Ferreira
YQYanfei Qi
Yanfei Qi
RFRodrigo A. Fraga-Silva
Rodrigo A. Fraga-Silva
CDCarlos Díez-Freire
Carlos Díez-Freire
MKMichael J. Katovich
Michael J. Katovich
Rationale: An activated vasoconstrictive, proliferative, and fibrotic axis of the renin angiotensin system (angiotensin-converting enzyme [ACE]/angiotensin [Ang]II/AngII type 1 receptor) has been implicated in the pathophysiology of pulmonary fibrosis (PF) and pulmonary hypertension (PH). The recent discovery of a counterregulatory axis of the renin angiotensin system composed of ACE2/Ang-(1–7)/Mas has led us to examine the role of this vasoprotective axis on such disorders. Objectives: We hypothesized that Ang-(1–7) treatment would exert protective effects against PF and PH. Methods: Lentiviral packaged Ang-(1–7) fusion gene or ACE2 cDNA was intratracheally administered into the lungs of male Sprague Dawley rats. Two weeks after gene transfer, animals received bleomycin (2.5 mg/kg). In a subsequent study, animals were administered monocrotaline (MCT, 50 mg/kg). Measurements and Main Results: In the PF study, bleomycin administration resulted in a significant increase in right ventricular systolic pressure, which was associated with the development of right ventricular hypertrophy. The lungs of these animals also exhibited excessive collagen deposition, decreased expression of ACE and ACE2, increased mRNA levels for transforming growth factor β and other proinflammatory cytokines, and increased protein levels of the AT1R. Overexpression of Ang-(1–7) significantly prevented all the above-mentioned pathophysiological conditions. Similar protective effects were also obtained with ACE2 overexpression. In the PH study, rats injected with MCT developed elevated right ventricular systolic pressure, right ventricular hypertrophy, right ventricular fibrosis, and pulmonary vascular remodeling, all of which were attenuated by Ang-(1–7) overexpression. Blockade of the Mas receptor abolished the beneficial effects of Ang-(1–7) against MCT-induced PH. Conclusions: Our observations demonstrate a cardiopulmonary protective role for the ACE2/Ang-(1–7)/Mas axis in the treatment of lung disorders.

1 April 2011 in American Journal of Physiology-Regulatory, Integrative and Comparative Physiology
Verified
Journal Article
Open access
PDF file
PXPing Xu
Ping Xu
Srinivas SriramulaSrinivas Sriramula
Srinivas Sriramula
ELEric Lazartigues
Eric Lazartigues
The last decade has seen the discovery of several new components of the renin-angiotensin system (RAS). Among them, angiotensin converting enzyme-2 (ACE2) and the Mas receptor have forced a reevaluation of the original cascade and led to the emergence of a new arm of the RAS: the ACE2/ANG-(1–7)/Mas axis. Accordingly, the new system is now seen as a balance between a provasoconstrictor, profibrotic, progrowth axis (ACE/ANG-II/AT1receptor) and a provasodilatory, antifibrotic, antigrowth arm (ACE2/ANG-(1–7)/Mas receptor). Already, this simplistic vision is evolving and new components are branching out upstream [ANG-(1–12) and (pro)renin receptor] and downstream (angiotensin-IV and other angiotensin peptides) of the classical cascade. In this review, we will summarize the role of the ACE2/ANG-(1–7)/Mas receptor, focusing on the central nervous system with respect to cardiovascular diseases such as hypertension, chronic heart failure, and stroke, as well as neurological diseases. In addition, we will discuss the new pharmacological (antagonists, agonists, activators) and genomic (knockout and transgenic animals) tools that are currently available. Finally, we will review the latest data regarding the various signaling pathways downstream of the Mas receptor.

1 December 2014 in Hypertension
Verified
Journal Article
Open access
PDF file
MDMatthew R. Deshotels
Matthew R. Deshotels
HXHuijing Xia
Huijing Xia
Srinivas SriramulaSrinivas Sriramula
Srinivas Sriramula
ELEric Lazartigues
Eric Lazartigues
CFCatalin Filipeanu
Catalin Filipeanu
Angiotensin-converting enzyme type 2 (ACE2) is a pivotal component of the renin–angiotensin system, promoting the conversion of angiotensin II (Ang-II) to Ang-(1-7). We previously reported that decreased ACE2 expression and activity contributes to the development of Ang-II–mediated hypertension in mice. The present study aimed to investigate the mechanisms involved in ACE2 downregulation during neurogenic hypertension. In ACE2-transfected Neuro-2A cells, Ang-II treatment resulted in a significant attenuation of ACE2 enzymatic activity. Examination of the subcellular localization of ACE2 revealed that Ang-II treatment leads to ACE2 internalization and degradation into lysosomes. These effects were prevented by both the Ang-II type 1 receptor (AT 1 R) blocker losartan and the lysosomal inhibitor leupeptin. In contrast, in HEK293T cells, which lack endogenous AT 1 R, Ang-II failed to promote ACE2 internalization. Moreover, this effect could be induced after AT 1 R transfection. Furthermore, coimmunoprecipitation experiments demonstrated that AT 1 R and ACE2 form complexes, and these interactions were decreased by Ang-II treatment, which also enhanced ACE2 ubiquitination. In contrast, ACE2 activity was not changed by transfection of AT 2 or Mas receptors. In vivo, Ang-II–mediated hypertension was blunted by chronic infusion of leupeptin in wildtype C57Bl/6, but not in ACE2 knockout mice. Overall, this is the first demonstration that elevated Ang-II levels reduce ACE2 expression and activity by stimulation of lysosomal degradation through an AT 1 R-dependent mechanism.

1 June 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
AFAnderson J. Ferreira
Anderson J. Ferreira
VSVinayak Shenoy
Vinayak Shenoy
YYYoriko Yamazato
Yoriko Yamazato
Srinivas SriramulaSrinivas Sriramula
Srinivas Sriramula
JFJoseph Francis
Joseph Francis
MRMohan K. Raizada
Mohan K. Raizada
Rationale: It has been proposed that an activated renin angiotensin system (RAS) causes an imbalance between the vasoconstrictive and vasodilator mechanisms involving the pulmonary circulation leading to the development of pulmonary hypertension (PH). Recent studies have indicated that angiotensin-converting enzyme 2 (ACE2), a member of the vasoprotective axis of the RAS, plays a regulatory role in lung pathophysiology, including pulmonary fibrosis and acute lung disease. Based on these observations, we propose the hypothesis that activation of endogenous ACE2 can shift the balance from the vasoconstrictive, proliferative axis (ACE-Ang II-AT1R) to the vasoprotective axis [ACE2-Ang-(1–7)-Mas] of the RAS, resulting in the prevention of PH. Objectives: We have taken advantage of a recently discovered synthetic activator of ACE2, XNT (1-[(2-dimethylamino) ethylamino]-4-(hydroxymethyl)-7-[(4-methylphenyl) sulfonyl oxy]-9H-xanthene-9-one), to study its effects on monocrotaline-induced PH in rats to support this hypothesis. Methods: The cardiopulmonary effects of XNT were evaluated in monocrotaline-induced PH rat model. Measurements and Main Results: A single subcutaneous treatment of monocrotaline in rats resulted in elevated right ventricular systolic pressure, right ventricular hypertrophy, increased pulmonary vessel wall thickness, and interstitial fibrosis. These changes were associated with increases in the mRNA levels of renin, ACE, angiotensinogen, AT1 receptors, and proinflammatory cytokines. All these features of PH were prevented in these monocrotaline-treated rats by chronic treatment with XNT. In addition, XNT caused an increase in the antiinflammatory cytokine, IL-10. Conclusions: These observations provide conceptual support that activation of ACE2 by a small molecule can be a therapeutically relevant approach for treating and controlling PH.